(123 days)
The Beckman Coulter AU5800 Clinical Chemistry Analyzer is an automated chemistry analyzer that measures analytes such as Glucose, Magnesium, and Potassium in samples, in combination with appropriate reagents, calibrators, quality control (QC) material and other accessories. This system is for in vitro diagnostic use only. Applications include colorimetric, turbidimetric, latex agglutination, homogeneous enzyme immunoassay, and ion selective electrode.
The Glucose test system is for the quantitative measurement of glucose in human serum, plasma, urine and cerebrospinal fluid on Beckman Coulter AU analyzers. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.
The Potassium test system is for the quantitative measurement of potassium in serum, plasma, and urine. Measurements obtained by this device are used to monitor electrolyte balance in the diagnosis and treatment of diseases conditions characterized by low or high blood potassium levels.
The Magnesium test system is for the quantitative measurement of Magnesium in human serum, plasma and urine on Beckman Coulter AU analyzers. Magnesium measurements are used in the diagnosis and treatment of hypomagnesemia (abnormally low plasma levels of magnesium) and hypermagnesemia (abnormally high plasma levels of magnesium).
The AU5800 clinical chemistry analyzer is a fully automated, random access analyzer, designed for ultra-high throughput laboratories. This system is designed to suit varying workloads and is available in different configurations, from a one-single photometric module AU5810, up to a four-photometric module AU5840. The AU5800 analyzer measures analytes in samples using the same reagents, calibrators, quality control (QC) materials and other consumables used within the AU series of instruments. This ensures the same reliable results and references ranges across the AU family members. This system carries out automated analysis of serum, plasma, urine samples and other body fluids and automatically generates results. Electrolyte measurement is performed using a single or double cell lon Selective Electrode (ISE) which is also common among the other members of the AU family.
The provided 510(k) summary for the AU5800 Clinical Chemistry Analyzer describes a predicate device comparison and does not include acceptance criteria or a study design in the traditional sense of a standalone algorithm or a comparative effectiveness study involving human readers. Instead, it focuses on demonstrating substantial equivalence to a previously cleared device (AU2700 Clinical Chemistry Analyzer) through performance validations and comparisons of representative assays.
Here's an breakdown based on the information provided, recognizing that many requested fields are not applicable to this type of submission:
1. Table of Acceptance Criteria and Reported Device Performance
The submission does not explicitly state numerical acceptance criteria for the AU5800 against each specific performance metric (like accuracy, sensitivity, specificity, etc.) as would be seen for a novel device. Instead, the acceptance criterion is "demonstrate equivalence between the proposed AU5800 and the predicate device (AU2700)" across various performance parameters.
The reported performance is qualitative, stating that "The submission provides the data necessary to demonstrate this equivalence based on the performance validations and comparisons conducted between the representative reagents and analyzer platforms. Based on this data, the new AU5800 Chemistry Analyzer is substantially equivalent to the referenced predicate(s)."
The performance testing indicated for demonstrating equivalence includes:
| Performance Metric | Reported Device Performance (AU5800 vs. AU2700) |
|---|---|
| Linearity | Equivalence demonstrated |
| Precision | Equivalence demonstrated |
| Method Comparison | Equivalence demonstrated |
| Sensitivity | Equivalence demonstrated |
| Interference | Equivalence demonstrated |
| Reference Range | Equivalence demonstrated |
2. Sample Size Used for the Test Set and Data Provenance
The document states that "Representative assays from the AU chemistry menu were selected to demonstrate equivalency between the proposed AU5800 and the predicate device." However, specific sample sizes for the test sets (patient samples, controls, standards) used for each performance validation (linearity, precision, etc.) are not provided in this summary.
The data provenance is implicit: it's laboratory data generated internally by Beckman Coulter during the development and validation of the AU5800. The data is prospective in the sense that it was generated for the purpose of demonstrating equivalence for this submission. The country of origin is not specified, but given Beckman Coulter's location in Brea, CA, USA, it's likely primarily US-based, though this is not explicitly stated.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications
Not Applicable. This is an in vitro diagnostic (IVD) device for clinical chemistry analysis. Ground truth for chemical measurements is typically established through reference methods, certified reference materials (NIST SRMs are mentioned for traceability), and established analytical practices, not by expert human graders or reviewers in the way that, for example, an imaging AI would be.
4. Adjudication Method for the Test Set
Not Applicable. See point 3.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
No, a MRMC comparative effectiveness study was not done. This type of study is relevant for diagnostic imaging devices where human readers interpret results, sometimes with AI assistance. The AU5800 is a clinical chemistry analyzer that produces quantitative measurements, not interpretations requiring human reader input in the same way.
6. Standalone Performance Study (Algorithm Only Without Human-in-the-Loop Performance)
Yes, in essence, the entire submission describes standalone performance testing. The AU5800 is an automated analyzer. The "performance validation and comparisons conducted between the representative reagents and analyzer platforms" demonstrate the performance of the device itself (the "algorithm" being the instrument's analytical processes) in producing measurements. There is no human-in-the-loop component for the analytical process of the device itself; it is fully automated.
7. Type of Ground Truth Used
The ground truth for the performance validations, particularly for method comparison, linearity, and precision, would be established by:
- Predicate Device Results: For method comparison, the results obtained from the predicate AU2700 would serve as a comparative "ground truth" or reference to assess the agreement of the AU5800.
- Certified Reference Materials/Standards: For linearity and calibration, measurements against materials with known, accurately determined concentrations (e.g., NIST SRMs like 916a, 965a, 909a-2, 909b mentioned for traceability) are used.
- Established Analytical Methods: For accuracy and other parameters, results might be compared to recognized reference methods in clinical chemistry.
8. Sample Size for the Training Set
Not Applicable. The AU5800 is a clinical chemistry analyzer, not a machine learning or AI algorithm that requires a "training set" in the conventional sense of developing a predictive model. Its "training" is in its engineering design, calibration, and validation against known standards and the predicate device.
9. How the Ground Truth for the Training Set Was Established
Not Applicable. See point 8.
{0}------------------------------------------------
DEC 2 3 2011
510(k) Summary AU5800 Clinical Chemistry Analyzer
1.0 Submitted By:
David G. Davis Group Manager, Regulatory Affairs Beckman Coulter, Inc. 250 S. Kraemer Blvd. Mail Code: E2 SE.08 Brea, CA 92821 Telephone: (469) 236-8180 Fax: (714) 961-4234
2.0 Date Submitted
August 19, 2011
3.0 Device Name(s):
- 3.1 Proprietary Names AU5800 Clinical Chemistry Analyzer
3.2 Classification Name
Discrete photometric chemistry analyzer for clinical use [862.2160]
4.0 Legally Marketed Device
| Candidate(s) | Predicate | Manufacturer | DocumentNumber |
|---|---|---|---|
| AU5800 ClinicalChemistry Analyzer | AU2700 ClinicalChemistry Analyzer | Beckman Coulter,Inc. | K002982 |
The AU5800 Clinical Chemistry Analyzer is substantial equivalence to the AU2700 Clinical Chemistry Analyzer (Docket Number K002982), currently in commercial distribution.
Device Description 5.0
The AU5800 clinical chemistry analyzer is a fully automated, random access analyzer, designed for ultra-high throughput laboratories. This system is designed to suit varying workloads and is available in different configurations, from a one-single photometric module AU5810, up to a four-photometric module AU5840. The AU5800 analyzer measures analytes in samples using the same reagents, calibrators, quality control (QC) materials and other consumables used within the AU series of instruments. This ensures the same reliable results and references ranges across the AU family members. This system carries out automated analysis of serum, plasma, urine samples and other body fluids and automatically generates results. Electrolyte measurement is performed using a single or double cell lon Selective Electrode (ISE) which is also common among the other members of the AU family.
6.0 Intended Use
The Beckman Coulter AU5800 Clinical Chemistry Analyzer is an automated chemistry analyzer that measures analytes in samples, in combination with appropriate reagents, calibrators, quality control (QC) material and other accessories. This system is for in vitro
{1}------------------------------------------------
diagnostic use only. Applications include colorimetric, turbidimetric, latex agglutination, homogeneous enzyme immunoassay, and ion selective electrode.
7.0 Comparison to the Predicate
The AU5800 Clinical Chemistry System is a family member of the AU series of analyzers, The AU2700 (K002982) to which the substantial equivalence comparison is claimed. The devices have same / similar design and modes of operation. The key features are summarized in the following table.
| Predicate Device: | Proposed Device: | |
|---|---|---|
| Feature | AU2700 Clinical Chemistry System | AU5800 Clinical Chemistry Analyzer |
| Intended Use: | The Olympus AU2700 ClinicalChemistry Analyzer is a fullyautomated photometric analyzerintended for clinical laboratory use.Applications include colorimetric,Turbidimetric, latex agglutination, andhomogeneous enzyme immunoassay. | The Beckman Coulter AU5800Clinical Chemistry Analyzer is anautomated chemistry analyzer thatmeasures analytes in samples, incombination with appropriatereagents, calibrators, quality control(QC) material and other accessories.This system is for in vitro diagnosticuse only. Applications includecolorimetric, turbidimetric, latexagglutination, homogeneous enzymeimmunoassay, and ion selective electrode. |
| Methodology: | Analyzer, chemistry (photometric,discrete), for clinical use has beenclassified as Class I, JJE by theClinical Chemistry and ClinicalToxicology Devices Panel, (21 CFR862.2160). | Same as AU2700 |
| Sample Types: | Blood serum, urine, CSF, or Plasma | Same as AU2700 |
| Assay Type: | End Point, Kinetic, Ions SelectiveElectrode (ISE) Optional.Applications:Colorimetric, Turbidimetric, LatexAgglutination, Homogenous EIA. | Same as AU2700 |
| ReactantVolume: | 120μl to 430μl | 80μl to 287μl |
| Sample Volume | 1.6uL to 25.0 uL | 1.0 to 17.0 uL |
| Prevention ofSample CarryOver | Deionized Water Wash withContamination AvoidanceParameters and enhanced washingsequence | Same as AU2700New function: extra optional DI washsequence |
| Recognition ofSample | Read from the barcode | Same as AU2700 |
| Reagent On-board chemistries | Reagent 1 - 48 bottle capacityReagent 2 - 48 bottle capacity | Reagent 1 - 54 bottle capacityReagent 2 - 54 bottle capacity |
| Reagent Bottle | Reagent bottles with a capacity of15mL, 30 mL, 60 mL, 120mL, 180mL | Same as AU2700 |
| Reagent Volume | 15 to 250 µL (can be set by 1uL) | 10 to 170 µL (can be set by 1uL) |
| NormalPipette | 15 to 250 µL (can be set by 1uL) | 10 to 170 µL (can be set by 1uL) |
| Feature | Predicate Device:AU2700 Clinical Chemistry System | Proposed Device:AU5800 Clinical Chemistry Analyzer |
| DiluentVolume | 0,10 to 235 uL (can be set by 1uL)Max (reagent+diluent) less than 250uL | 0,10 to 160 uL (can be set by 1uL)Max (reagent+diluent) less than 170uL |
| Wave length (nm) | Halogen Lamp340 to 800 nm13 wavelengths: 340, 380, 410, 450, 480, 520, 540, 570, 600, 660, 700, 750 and 800 nm | Same as AU2700 |
| Cuvette | Square, glass cuvette6x5 mm (Inside)Capacity: 750 uLLight Path: 6mm | Square, glass cuvette4 x 5 mm (Inside)Capacity: 500 uLLight Path: 5mm |
| Cycle time ofphotometrymeasuring point | 28 points in 8.5 minutes (±.5 min) | Same as AU2700 |
{2}------------------------------------------------
Comparison testing
In order to further demonstrate the comparability of the Beckman AU2700 and the proposed new Beckman Coulter AU5800, the following reagent performance testing was performed on a representative number of assays:
Linearity Precision Method Comparison Sensitivity Interference Reference Range
The AU5800 chemistry analyzer uses same lon Selectrode (ISE) and reagents, as well as the same menu of reagents currently available on the AU2700. Representative assays from the AU chemistry menu were selected to demonstrate equivalency between the proposed AU5800 and the predicate device. The studies were selected from reviewing the applicable sections of FDA's eSubmitter software tool for instrument only submissions and utilizing the FDA's Guidance for Industry and FDA staff Replacement Reagent and Instrument Family Policy.
The remaining reagent application validations not presented within the 510(k) will be validated using risk management, design controls, and the principles from FDA's Guidance for Industry and FDA staff Replacement Reagent and Instrument Family Policy. The core validation principles are linearity, control/standard recovery, method comparison, precision, sensitivity, interference, prozone tolerance and onboard/calibration frequency studies. Reference ranges will be verified, where appropriate. No reagent application will be released to the market without the satisfactory completion of the validation process.
8.0 Summary of Performance Data
The submission provides the data necessary to demonstrate this equivalence based on the performance validations and comparisons conducted between the representative reagents and analyzer platforms. Based on this data, the new AU5800 Chemistry Analyzer is substantially equivalent to the referenced predicate(s).
{3}------------------------------------------------
Traceability
The traceability information in the reagent 510ks was updated via K043460 on the calibrator to align with the current IFU claims.
| Predicate Reagent 510k(s) | Calibrator 510(k) | Current IFU claim |
|---|---|---|
| Glucose traceability | Glucose traceability | Glucose traceability |
| NIST SRM 916a | NIST SRM 965a | NIST SRM 965a |
| Magnesium traceability | Magnesium traceability | Magnesium traceability |
| NIST SRM 909a-2 | NIST SRM 909b | NIST SRM 909b |
| Potassium traceability | Not impacted by modification | Potassium traceability |
| Not specified - but | Not specified - but | |
| gravimetrically prepared | gravimetrically prepared | |
| standard | standard |
The on-board claims were re-assessed on the AU2700 analyzer 510k, which is the predicate for the AU5800. In addition, the potassium on board claims were expanded through the design control process.
| Predicate Reagent 510(k) | AU2700 Instrument K003721 | Current IFU |
|---|---|---|
| Glucose on-board stability | Glucose on-board stability | Glucose on-board stability |
| 14 days | 30 days | 30 days |
| Magnesium on-board stability | Magnesium on-board stability | Magnesium on-board stability |
| 30 days | 7 days | 7 days |
| Potassium on-board stability | Not mentioned in submission | Potassium on-board stability |
| 30 days | 90 days |
{4}------------------------------------------------
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is a stylized graphic of what appears to be an abstract human form or a symbol representing human services.
10903 New Hampshire Avenue Silver Spring, MD 20993
Beckman Coulter, Inc. c/o David G. Davis 250 S. Kraemer Blvd. Mail Code: E2.SE.08 Brea, CA 92821
DEC 2 3 2011
Re: K112412 Trade name:
AU5800 Clinical Chemistry Analyzer
Regulation Number: 21 CFR §862.1345 Glucose test system Regulation Name: Regulatory Class: Class II Product Codes: CFR, CEM, JGJ, JJE Dated: November 11, 2011 Received: November 14, 2011
Dear Mr. Davis.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
{5}------------------------------------------------
Page 2
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance ...
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm
Sincerely yours,
Courney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{6}------------------------------------------------
Indication for Use
510(k) Number (K112412):
Device Name: AU5800 Clinical Chemistry Analyzer
Indication For Use:
The Beckman Coulter AU5800 Clinical Chemistry Analyzer is an automated chemistry analyzer that measures analytes such as Glucose, Magnesium, and Potassium in samples, in combination with appropriate reagents, calibrators, quality control (QC) material and other accessories. This system is for in vitro diagnostic use only. Applications include colorimetric, turbidimetric, latex agglutination, homogeneous enzyme immunoassay, and ion selective electrode.
The Glucose test system is for the quantitative measurement of glucose in human serum, plasma, urine and cerebrospinal fluid on Beckman Coulter AU analyzers. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.
The Potassium test system is for the quantitative measurement of potassium in serum, plasma, and urine. Measurements obtained by this device are used to monitor electrolyte balance in the diagnosis and treatment of diseases conditions characterized by low or high blood potassium levels.
The Magnesium test system is for the quantitative measurement of Magnesium in human serum, plasma and urine on Beckman Coulter AU analyzers. Magnesium measurements are used in the diagnosis and treatment of hypomagnesemia (abnormally low plasma levels of magnesium) and hypermagnesemia (abnormally high plasma levels of magnesium).
Prescription Use _____________________________________________________________________________________________________________________________________________________________ X (21 CFR Part 801 Subpart D) And/Or
Over the Counter Use _________________________________________________________________________________________________________________________________________________________ (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OVD)
Signature
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K112412
§ 862.1600 Potassium test system.
(a)
Identification. A potassium test system is a device intended to measure potassium in serum, plasma, and urine. Measurements obtained by this device are used to monitor electrolyte balance in the diagnosis and treatment of diseases conditions characterized by low or high blood potassium levels.(b)
Classification. Class II.